Evidence map›GLP-1 receptor agonists × body weight & composition›PMID 40069849›Full record

Trial reportDiabetes, obesity & metabolism2025

Efficacy and safety of once-weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial.

Weijun Gu, Yibing Lu, Xinhua Ye, Guoyue Yuan, Dongmei Liu, Zewei Shen, Ning Zu, Yiming Mu

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2025. The graph read 2 numbers from its abstract, feeding 1 cell of the map: it supports the treatment in 1. It reports registered trial NCT04251156. Cited by 2 papers, 1 of them a synthesis that pooled it.

2numbers the graph read from it
1cell of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

Ratios

← favours the comparatorfavours the treatment →
24101 · no effect
Proportion of participants who achieved ≥5% reduction in body weight from baselinesemaglutide 2.4 mg vs placebo, in Chinese participantsfavours the treatment · obesity, t2dfeeds one cell of the map
OR 16.18.40 to 30.9p < 0.0001
At Week 44, a greater proportion of participants treated with semaglutide 2.4 mg achieved ≥5% body weight loss versus placebo (85.4% vs. 26.8%): odds ratio 16.1; 95% CI 8.4, 30.9; p < 0.0001.
FeedsGLP-1 receptor agonists×body weight & composition

Differences

← favours the treatmentfavours the comparator →
-10.20 · no effect
Change in mean body weight from baseline to Week 44semaglutide 2.4 mg vs placebo, in Chinese participantsfavours the treatment · obesity, t2dfeeds one cell of the map
Δ -8.30-10.2 to -6.40p < 0.0001
Estimated change in mean body weight from baseline to Week 44 was -11.8% with semaglutide 2.4 mg versus -3.5% with placebo (estimated treatment difference -8.3%; 95% confidence interval [CI] -10.2, -6.4; p < 0.0001).
FeedsGLP-1 receptor agonists×body weight & composition

clause the extractor read what became the number

2 · Its place on the map

Where it lands on the map

Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.

supports the treatmentfavours the comparatorno clear differenceread, but no usable result
3 · What it changes

What it adds to each cell

For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.

GLP-1 receptor agonists×body weight & composition

SupportsOpen on the map →What to test next →

40 readable studies in this cell: 83 favour the treatment, 15 find no difference, 11 favour the comparator.

Belief with this paper
0.90replicated · 64 families support, 7 contradict · against placebo
Without it
0.90This paper does not move the number.
← favours the comparatorfavours the treatment →
1 · no effect
This paper375 enrolled · 2020
OR 16.18.40 to 30.9
NCT05579249500 enrolled · 2023
OR 3.182.12 to 4.78
4 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04251156 phase3completed

Effect and Safety of Semaglutide 2.4 mg Once-weekly on Weight Management in Subjects With Overweight or Obesity.

Ran2020Enrolled375Registered outcomes43Posted comparisons2ConditionsDiabetes Mellitus, Type 2, Obesity, OverweightArmsPlacebo (semaglutide), semaglutide
PMID 38330988other papers from this trial
Open the trial in the graph
5 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
6 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

7 · Who and what money

Authors and funding

8 authors.

Weijun GuDepartment of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.ORCID 0000-0001-8690-645X
Yibing LuDepartment of Endocrinology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xinhua YeDepartment of Endocrinology, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical University, Changzhou, China.
Guoyue YuanDepartment of Endocrinology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.ORCID 0000-0003-0822-6066
Dongmei LiuNovo Nordisk (China) Pharmaceuticals Co., Ltd., Beijing, China.
Zewei ShenNovo Nordisk (China) Pharmaceuticals Co., Ltd., Beijing, China.
Ning ZuNovo Nordisk (China) Pharmaceuticals Co., Ltd., Beijing, China.
Yiming MuDepartment of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.ORCID 0000-0002-3344-3540

Funding

Novo Nordisk A/S
8 · The paper itself

Abstract

The marked sentences are the ones the graph read a number from.

aimTo evaluate the efficacy and safety of semaglutide 2.4 mg versus placebo for weight management in a population of Chinese adults with overweight or obesity. MATERIALS AND

methodsIn STEP 7 (NCT04251156), a double-blind, phase 3a trial, adults from a predominantly East Asian population with overweight or obesity, with or without type 2 diabetes, were randomized 2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo for 44 weeks as an adjunct to a reduced-calorie diet and increased physical activity. This prespecified analysis evaluated Chinese participants in STEP 7. The primary endpoints were percentage change in body weight from baseline to Week 44 and the proportion of participants who achieved ≥5% reduction in body weight from baseline.

resultsOverall, 195 Chinese participants were randomized to semaglutide 2.4 mg and 105 to placebo. Estimated change in mean body weight from baseline to Week 44 was -11.8% with semaglutide 2.4 mg versus -3.5% with placebo (estimated treatment difference -8.3%; 95% confidence interval [CI] -10.2, -6.4; p < 0.0001). At Week 44, a greater proportion of participants treated with semaglutide 2.4 mg achieved ≥5% body weight loss versus placebo (85.4% vs. 26.8%): odds ratio 16.1; 95% CI 8.4, 30.9; p < 0.0001. Adverse events were reported by 92.3% of semaglutide-treated participants and 82.9% of placebo-treated participants, the most common of which were gastrointestinal disorders (126/195, 64.6% vs. 35/105, 33.3%).

conclusionsThese data demonstrate beneficial effects of semaglutide 2.4 mg versus placebo, supporting its use in an adult Chinese population with overweight or obesity.

Indexed as

Anti-Obesity AgentsGlucagon-Like PeptidesObesityOverweightAdultAgedChinaDiabetes Mellitus, Type 2Double-Blind MethodDrug Administration ScheduleFemaleGlucagon-Like Peptide 1HumansMaleMiddle AgedSemaglutideAnti-Obesity AgentsGlucagon-Like Peptide 1Glucagon-Like PeptidesSemaglutideantiobesity drugclinical trialGLP‐1 analoguephase III studysemaglutideweight management

Identifiers

PMID40069849
PMCPMC11964988

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.